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Abstract
Objective
To revise the 1999 Airlie House consensus guidelines for the design and implementation of
preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS).
Methods
A consensus committee comprising 140 key members of the international ALS community
(ALS researchers, clinicians, patient representatives, research funding representatives, industry,
and regulatory agencies) addressed 9 areas of need within ALS research: (1) preclinical studies;
(2) biological and phenotypic heterogeneity; (3) outcome measures; (4) disease-modifying
and symptomatic interventions; (5) recruitment and retention; (6) biomarkers; (7) clinical trial
phases; (8) beyond traditional trial designs; and (9) statistical considerations. Assigned to 1 of 8
sections, committee members generated a draft set of guidelines based on a “background” of
developing a (pre)clinical question and a “rationale” outlining the evidence and expert opinion.
Following a 2-day, face-to-face workshop at the Airlie House Conference Center, a modified
Delphi process was used to develop draft consensus research guidelines, which were sub-
sequently reviewed and modified based on comments from the public. Statistical experts
drafted a separate document of statistical considerations (section 9).
Results
In this report, we summarize 112 guidelines and their associated backgrounds and rationales.
The full list of guidelines, the statistical considerations, and a glossary of terms can be found in
data available fromDryad (appendices e-3–e-5, doi.org/10.5061/dryad.32q9q5d). The authors
prioritized 15 guidelines with the greatest potential to improve ALS clinical research.
Conclusion
The revised Airlie House ALS Clinical Trials Consensus Guidelines should serve to improve
clinical trial design and accelerate the development of effective treatments for patients with ALS.
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Consensus guidelines for performing clinical trials in amyo-
trophic lateral sclerosis (ALS) were published in 1999, only
a few years after approval of riluzole, the first drug to treat
ALS.1 Since then, more than 40 clinical trials have provided
clinical trial experience, and 2 additional drugs have been
approved: dextromethorphan/quinidine for symptomatic
treatment of pseudobulbar affect and the disease-modifying
drug edaravone.2,3 Riluzole provides amodest prolongation of
survival and edaravone a modest slowing of functional decline
in a selected cohort, but there is still an urgent need for more
effective therapies.
The following advances have raised expectations and may
improve ALS trial success: (1) the ability to model human
disease using induced pluripotent stem cell lines4,5; (2) the
discovery of an increasing number of ALS-associated genes6;
(3) recognition of ALS as a phenotypically, etiologically, and
biologically heterogeneous disease6,7; (4) the development of
techniques to analyze “big data” to subclassify ALS more ac-
curately and generate personalized prediction models8,9; and
(5) the emergence of new outcome measures such as disease
staging and technology-assisted outcomes.10,11 In addition,
rigorous methods of establishing trial guidelines have evolved.
The modified Delphi process has become a common method
of achieving consensus, particularly when scientific evidence is
suboptimal.12
In 2016, international stakeholders met at the Airlie House
Conference Center, Warrenton, VA, to develop new ALS
clinical trials research guidelines using the modified Delphi
method.
Methods
Following the proposal to revise the 1999 guidelines at the
ALS Research Group Summit Meeting, held October 2014,
an Organizing Committee and Advisory Board were assem-
bled including international stakeholders in ALS research.
The Organizing Committee identified 9 areas to be
addressed: (1) preclinical studies; (2) biological and pheno-
typic heterogeneity; (3) outcome measures; (4) therapeutic
and symptomatic interventions; (5) recruitment and re-
tention; (6) biomarkers; (7) clinical trial phases; (8) beyond
traditional trial designs; and (9) statistical considerations (see
appendix 1 for the leadership and appendix 2 for membership
of each section).
The first stage of developing the guidelines involved identi-
fying key members of the international ALS community, in-
cluding researchers, clinicians, health care professionals,
patients and caregivers, representatives from patient advocacy
groups, industry, funding agencies, and regulatory agencies.
Each member was assigned to 1 of the 8 nonstatistical sections
with a maximum of 20 people/section. Seven experts in sta-
tistics produced a separate document on Statistical Consid-
erations. These individuals also participated in 1 or 2 of the
nonstatistical sections. Under the guidance of the section
leaders, the nonstatistical sections independently identified
key areas to be addressed within their topic. This resulted in
a draft document including a background describing the con-
text for each topic, a series of preliminary evidence-informed
guidelines, and a rationale providing the evidence and expert
opinion supporting each guideline. Each statement within the
rationale was classified as one of the following: (1) supported
by evidence (with appropriate references); (2) accepted on
principle (if the statement is widely believed to be true by the
ALS community even in the absence of conclusive evidence);
or (3) an inference logically derived from other premises
(deductive conclusion).
The second stage of developing guidelines was a face-to-face
meeting of stakeholders that took place in the Airlie House
Conference Center in Warrenton, VA, in March 2016.
Appointed leaders from each group presented the draft
guidelines, which was followed by a discussion by all confer-
ence participants. Discussions focused on the logical rationale
for the guidelines, validity of the axiomatic and evidence
statements, logical basis of any inferences, and the absence of
any necessary premises. Following the discussion, additional
comments on each of the guidelines were submitted anony-
mously. Each section met again independently to review the
feedback and provide modifications to their document’s
background, rationale, or guidelines. This resulted in a second
draft document from each of the 8 sections.
The third stage of developing guidelines included a month-
long public comment period (August 2016) on the 8 non-
statistical documents. Each section met to review the publicly
provided anonymous feedback, modify content as needed,
and provide a written explanation for actions taken or not
taken to modify the document in response to the feedback.
This resulted in a third draft document from each of the
sections (data available fromDryad, appendix e-4, doi.org/10.
5061/dryad.32q9q5d).
The fourth stage of developing the guidelines entailed
a modified Delphi consensus process in which the guidelines
and supporting rationales were reviewed under the guidance
of G.G. (American Academy of Neurology, Guideline
Methodologist).12 During this stage, the members of each
Glossary
ALS = amyotrophic lateral sclerosis; NIV = noninvasive ventilation; PALS = people living with amyotrophic lateral sclerosis;
QOL = quality of life.
Neurology.org/N Neurology | Volume 92, Number 14 | April 2, 2019 e1611
section provided anonymous judgments regarding the co-
gency of the rationales supporting the guidelines and the
anticipated impact of each guideline. Cogency issues were
addressed by answering the following yes/no questions:
1. Assuming all premises are true, is the rationale logical?
2. Are the evidence-based statements correct?
3. Do you agree with the stipulated axioms?
4. Are the internal inferences correct?
5. Are important premises missing from the rationale?
If all 5 questions gained an affirmative response from 80% or
more of the respondents, consensus was declared.
Next, the respondents were asked to assess, using a 4-point
ordinal score, how adherence to the guidelines would affect
the following domains:
1. The benefit relative to harm ratio (large, moderate, small,
none)
2. Feasibility (always, usually, occasionally, rarely)
3. Cost relative to benefit (small, moderate, large, very
large)
Consensus on the guidelines was declared when 80% of
respondents rated the effect of adherence within 1 ordinal
rank in all 3 domains. If consensus was not achieved after the
first round of voting, guidelines were reviewed, modified, and
subjected to subsequent rounds of voting, up to amaximum of
3. After consensus was attained, a guideline was rejected if the
lowest modal score in any domain indicated the lowest level of
effect (no benefit, rarely feasible, very large cost). Otherwise,
the strength of the guideline was indicated by the auxiliary
verbs may, should, or must. Guidelines were designated by
“may” when the lowest modal score in any domain was in the
second lowest category (small benefit, occasionally feasible,
large cost) and indicated reasonable options for ALS
researchers. Guidelines designated by “should” resulted when
the lowest modal score in any domain was in the second
highest category (moderate benefit, usually feasible, moderate
cost) and indicated actions ALS researchers would usually
follow. Guidelines were designated by “must” when modal
scores in all domains were in the highest category (large
benefit, always feasible, small cost) and indicated actions
would almost always follow.
This process generated a final list of 112 guidelines. Because of
the large number of guidelines generated, the section leaders
and conference organizers were asked to prioritize 15 guide-
lines with the greatest potential to improve ALS clinical re-
search. These high-priority guidelines are summarized in the
results section below. Section 9 on statistical guidelines was
not developed using the modified Delphi process.
We emphasize that these are guidelines that were not de-
veloped using the American Academy of Neurology’s practice
guideline development process.
Results
For a full review of the ALS Clinical Trials Guidelines,
the reader is referred to data available from Dryad (appen-
dices e-4 and e-5, doi.org/10.5061/dryad.32q9q5d). A sum-
mary of the most important guidelines and those prioritized
(marked with *) by section leaders and conference organizers
are presented below.
Preclinical studies
Background
Demonstrations of efficacy in animal models have not led
to successful therapies in humans. The development of
drugs has been hampered by genetically engineered animal
models that do not reflect the complete spectrum of phe-
notypes present in people living with ALS (PALS) and by
inconsistency in the design and execution of preclinical
studies, as well as a paucity of naturally occurring ALS
animal models.13–16
Our ability to model human disease using induced pluripotent
stem cell lines, 3-dimensional tissue models, and other com-
plex in vitro systems, has improved dramatically.4,5 Such
cellular model systems permit confirmation of target en-
gagement but may not effectively model the complex patho-
physiology of ALS.
Guidelines
c *Investigators should provide a firm biological rationale
for moving a therapeutic candidate into human trials.
This rationale may arise from data obtained in engineered
animal models or cellular models, naturally occurring
ALS-like animal diseases, and/or from human clinical
data.
c Investigators should use preclinical models for assess-
ment of (1) efficacy (ALS models) or (2) safety, toxicity,
bioavailability, and biodistribution (can also be con-
ducted in wild-type animals/cells).
c Investigators may prioritize development of model
systems that recapitulate key pathologies seen in sporadic
ALS, such as cytoplasmic TDP-43 (TAR DNA-binding
protein 43) mislocalization.
c To enhance existing in vitro models, investigators may
develop model systems with multiple relevant cell types
in organoid-like or similar 3-dimensional structures to
improve cellular maturity and to study noncell autono-
mous disease processes.
c *Investigators should develop preclinical pharmacody-
namic and target engagement biomarkers for therapeutic
candidates to inform the design of human trials whenever
possible.
c Investigators should develop, publish, and adhere to best
practice guidelines for the use of fully characterized
preclinical ALS models.
c *Investigators and research funders should commit effort,
time, and funds to independent preclinical validation
studies of therapeutic candidates, and publish positive
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and negative results, ideally in a peer-reviewed, open-
access format.
Biological and phenotypic heterogeneity
Background
Incident cases (all new cases diagnosed within a specific time
frame [usually 6 months to a year after diagnosis]) have
a worse prognosis than prevalent cases (all existing diagnosed
cases). Prevalent cases are generally younger and more likely
to have a spinal presentation and slower progression.17–19
While the clinical presentation of familial cases resembles that
of sporadic cases, specific gene abnormalities may influence
the clinical phenotype and prognosis. Genetic analyses could
be performed before and during trials in cases of unexpected
response since little is known regarding the genetic-epigenetic
interplay or modifier gene polymorphisms in ALS.
More than 30% of PALSmanifest cognitive impairment, which
may exacerbate functional decline and lead to earlier death.20
There are multiple other factors that affect phenotype and
survival, but stratification can realistically be performed for only
3 or 4 factors, depending on the size of the trial. The issue of
having to stratify for too many variables could be overcome by
the use of a reliable prediction model of prognosis.9
Guidelines
c Investigators should preferentially enroll PALS with
“clinically definite,” “clinically probable,” “probable-
laboratory supported,” and “clinically possible” ALS,
who have a short interval from disease onset to trial entry.
c Investigators should stratify for genetic factors and cognitive
(especially executive function) and behavioral impairments.
c *Investigators should collect DNA from all participants,
when possible, to allow genetic post hoc analyses, which
may reveal important stratification or screening factors
for a subsequent clinical trial(s).
c Investigators should choose to stratify for factors most
relevant to the outcome measure of the trial.
c Investigators could stratify based on prognostic systems
or prediction models.
Outcome measures
Background
For a primary outcome, an endpoint is needed in phase 3 clinical
trials that is robust, can be reliably measured, and is clinically
meaningful. Survival and functional scales fulfill these criteria but
have limitations: survival trials require large numbers of patients
with long follow-up time, while functional scales are limited be-
cause of deaths and variable follow-up periods with resulting
missing data points.21–23 Other or additional outcome measures
will have to be included, explored, or validated. A short back-
ground of each of these (potential) outcome measures is below.
An endpoint combining survival and function may adjust for
dropouts and increase power.24,25
Muscle strength: As progressive weakness is the cardinal
symptom of ALS, accurate measurement of muscle strength
represents a direct measure of disease status.24–26
Respiratory failure carries a poor prognosis and is the most
common cause of death in ALS.
Quality of life (QOL) is an important part of human existence
and a critical outcome of treatment for PALS.27,28
Cognitive and behavioral abnormalities have been recognized in
many patients with ALS and can be debilitating.29
Motor neuron function: Electrophysiology can assess the
function of the upper and lower motor neurons.
Staging: Various methods of clinically staging ALS have been
proposed.10,30–32
Responder analyses: With our improved understanding of ALS
as a multifactorial disorder, responder analyses have the po-
tential to demonstrate beneficial effects of a proposed treat-
ment on a subset of PALS with a shared unique
pathophysiology. Such benefits may be missed in a broader
analysis that pools all PALS.
Technology-assisted outcomes of mobility through use of ped-
ometers, accelerometers, activity trackers, andmotion analysis
systems could be used to more objectively quantify daily lo-
comotor activities.
Networks (NEALS [Northeast ALS Consortium], TRICALS
[Trial Research Initiative to Cure ALS]) have been estab-
lished to organize adequate training and certification to en-
sure quality control of outcome measures.
Guidelines
c Investigators should include either a survival analysis or
functional assessment as the primary outcome measure in
phase 3 trials with the alternative included as a secondary
outcome.
c Investigators may include a combined survival/functional
outcome measure as an exploratory endpoint.
c Investigators may include quantitative strength assess-
ments as a primary outcome measure.
c Investigators may include a health-independent, ALS-
specific QOL scale as a primary outcome measure in
symptomatic management trials.
c Investigators may include assessments of cognitive or
behavioral function as primary or secondary outcome
measures.
c Investigators should use measures of pulmonary function
as an outcome; these may be used as a primary outcome.
c Investigators may use electrophysiology measures, elec-
trical impedance myography, health-independent ALS-
specific QOL scales, bulbar assessment scales, staging, and
caregiver measurements as secondary outcome measures.
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c Investigators may include responder analyses; the param-
eters and definitions of a “responder” should be specified
prior to trial initiation.
c Investigators may include technology-assisted measure-
ments as exploratory endpoints.
c *All study examiners should undergo training to ensure
uniformity of study procedures across sites and across
time.
Disease-modifying and
symptomatic interventions
Background
Symptomatic interventions are those that do not modify
the underlying pathophysiology but that treat specific
symptoms. In trials of disease-modifying interventions,
symptom management (e.g., with noninvasive ventilation
[NIV],33 nutrition, and gastrostomy34) may alter results
obtained using validated disease scales and affect other trial
outcomes including survival. Relatively few studies of
symptomatic therapies or medical devices have been
completed.
ALS is the result of a complex cascade involving multiple cell
types and various mechanisms converging to result in motor
neuron cell death.35 Thus, novel therapies could be aimed at
multiple aspects of the disease cascade (i.e., multidrug trials).
Combination drug therapies have proven effective for other
diseases (e.g., HIV, lymphoma), even when the agents in-
volved have not shown individual efficacy. Hence, it may not
be necessary to demonstrate efficacy separately for single
drugs prior to using them in multidrug ALS trials. Disease-
specific biomarkers relative to the various mechanisms being
tested will be needed to assess the contribution of each drug in
a multidrug trial.36
Guidelines
c *When a symptomatic intervention is effective (e.g.,
NIV), the investigator should consider permitting its use
for trial participants. Ethical implications and challenges
to enrollment should be carefully considered if such
a symptomatic intervention is used as an exclusion factor
for participation.
c Investigators should plan a priori analyses and standard-
ize and record use of interventions known to affect
disease course within a clinical trial (e.g., NIV, gastro-
stomy placement).
c *Investigators should conduct rigorous randomized
controlled trials of symptomatic therapies or medical
devices and utilize a patient-reported outcome and
QOL measure as either a primary or secondary
outcome in such trials.
c Investigators may use multidrug therapy in ALS clinical
trial design.
c Trialists may use disease-specific assays for any combi-
nation drug trial to assess both clinical efficacy and the
individual pathophysiologic mechanisms.
Recruitment and retention
Background
Clinical trials require the enthusiasm of PALS and caregivers
to support enrollment, minimize missing data, and avoid
dropout. Leading clinical trial groups from fields outside of
ALS are increasingly partnering with patients and caregivers
on the development of protocols, recruitment strategies, and
publications.37,38
There is increasing pressure by PALS and caregivers to obtain
access to treatments, including investigational therapies,
which have not been adequately studied and thus, are not
known to be effective. History demonstrates that most in-
vestigational therapies will ultimately be determined in-
effective by well-designed clinical trials. Most therapies cause
side effects, and phase 1 studies commonly underestimate the
risks from new therapies because of small sample size and
limited generalizability.
The Right to Try Act of 2017 was signed into law on May 30,
2018. Our full consensus-based guidelines were finalized before
this time. We have added a comment on the approved legis-
lation in the full guidelines found in data available from Dryad
(appendix e-4, page 45, doi.org/10.5061/dryad.32q9q5d).
Guidelines
c *Investigators should ensure ALS clinical trial results are
published in open access journals.
c All efforts should be made to improve trial design in ways
that expand the number of PALS receiving the experi-
mental therapy, including limiting use of a placebo arm.
c Investigators should explain to PALS that withdrawing
from clinical trials may reduce the certainty of results.
c Because safety and efficacy of experimental drugs are not
demonstrated in phase 1 clinical trials, drug developers
should move as quickly as possible to subsequent phase 2
trials where more reliable data on these parameters are
obtained.
c Physicians may counsel PALS requesting investigational
therapies that (1) because most investigational therapies
are ultimately found to be ineffective and have side
effects, PALS are more likely to be harmed than helped by
such treatments, (2) physicians are not obliged to
prescribe such therapies outside a clinical trial designed
to establish safety and efficacy, (3) insurers are unlikely to
pay for such therapies, and (4) manufacturers are not
obliged to make such therapies available.
Biomarkers
Background
Use of biomarkers, defined as “characteristics that are objec-
tively measured and evaluated as indicators of normal bi-
ological processes, pathological processes, or biological
responses to therapeutic interventions,” may facilitate greater
success of ALS clinical trials. Various types of biomarkers are
recognized (table), each with a different potential application
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in the clinical trial setting. In considering the potential use of
biomarkers, a distinction should be made between generic
biomarkers of motor neuron loss (e.g., neurofilaments) and
biomarkers that might be specific to a drug with a particular
mechanism of action (e.g., cytokines as markers of in-
flammation). A plethora of biomarker candidates (biological
fluids, neuroimaging, and neurophysiologic studies) have
emerged, but none have been formally validated for routine
clinical or therapeutic trial use in ALS. In addition to ensuring
that these candidates meet minimum methodologic criteria,
pragmatic issues such as patient tolerability, burden of par-
ticipation, investigator time, cost, complexity, need for spe-
cialized equipment, training, and certification will also require
consideration.
Guidelines
c *In designing and implementing ALS clinical trials,
investigators should incorporate (to the extent that they
have been developed and validated as such) predictive
biomarkers, prognostic biomarkers, and, especially in
phase 2 trials, pharmacodynamic biomarkers (table) (3
prioritized guidelines [6-1-1, 6-1-2, and 6-1-3] on pages
46 and 47 of the full guidelines found in data available
fromDryad, appendix e-4, doi.org/10.5061/dryad.32q9q5d).
c *Investigators should ensure that biomarkers are quantifi-
able and can be measured reliably using standardized
operating procedures across multiple centers, accounting
for relevant sources of variability, including intra- and
intersubject, intra- and interassessment (assay, evaluator,
scanner), and interlaboratory/site.
c Investigators should accumulate additional experimental
data to support the use of biomarkers in future clinical
trials for go/no-go decisions.
Clinical trial phases
Background
The process of investigating novel treatment consists of 3 phases:
The purpose of phase 1 studies is to define the short-term
safety profile, pharmacokinetic profile, and maximum toler-
ated dose. Many times, phase 1 trials incorporate single as-
cending dose and multiple ascending dose designs to
accomplish these goals.
Phase 2 trials assess optimal dosing, expand pharmacokinetics,
determine whether a therapy has the desired biological effect,
monitor safety and tolerability, and whether a potential
therapy reaches and affects its intended target.39,40 Clinical
efficacy is not the main goal of phase 2 studies.39,41,42
Phase 3 trials aim to demonstrate efficacy. The long track
record of negative phase 3 trials emphasizes the need for
innovative trial design.2,39 Randomized, placebo-controlled
clinical trials remain the most robust way to demonstrate
efficacy of an intervention.2 Alternatively, there are study
designs that assess efficacy without the use of placebo con-
trols, which can be explored.43
Alternative study designs (adaptive designs, seamless phase 2/3
designs, enrichment designs, or futility designs) (see also
statistical considerations in data available from Dryad, ap-
pendix e-5, doi.org/10.5061/dryad.32q9q5d) can provide an
opportunity to more efficiently and rapidly conduct clinical
trials to evaluate potential therapies.
There are distinct challenges and opportunities in performing
early-phase gene and stem cell therapy trials in ALS, which re-
quire special approaches and unique trial designs for testing these
therapies. When small subpopulations are targeted or a large
effect is expected, as with certain gene therapy approaches, tra-
ditional concurrent placebo controls may not be feasible.
Guidelines
c In phase 1 studies, investigators should incorporate single
ascending dose and multiple ascending dose designs to
evaluate safety, pharmacokinetic profile, and maximum
tolerated dose. Investigators may include a placebo
control to evaluate the adverse event rate but may omit
placebo when its inclusion involves excessive risk. They
may choose to conduct studies in healthy volunteers or
PALS depending on the nature of the intervention and
goals of the study.
c *Investigators should carefully review phase 2 trial results
and choose a primary endpoint that is clinically
meaningful and adequately powered for phase 3.
c Investigators may move from phase 2 to phase 3 with at
least adequate information on safety and tolerability, and
Table Types of biomarkers
Type of biomarker Description
Diagnostic A diagnostic biomarker is a disease characteristic that categorizes a person by the presence or absence of a specific disease.
Prognostic A prognostic biomarker is a baseline characteristic that categorizes patients by risk of a disease or progression of a disease.
Predictive A predictive biomarker is a baseline characteristic that categorizes patients by their likelihood of response to a particular treatment.
Pharmacodynamic A pharmacodynamic biomarker is one that demonstrates a biological response in a patient who has received a therapeutic
intervention.
Disease
progression
A progression biomarker is a biomarker that changes as disease advances.
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should move forward if there is safety and tolerability in
combination with (1) information regarding pharmaco-
dynamically optimal dose, (2) evidence of target
engagement, and/or (3) evidence of clinical efficacy.
c Investigators may assess biological effect and/or pre-
liminary efficacy, even using novel methods (e.g.,
predictive algorithms or exploratory biomarkers), to
support a decision to move a therapy to phase 3 trials.
c *When designing phase 3 trials, investigators should seek to
use placebo-control before considering alternative designs.
c Investigators should work with biostatisticians to
consider alternative designs.
c Investigators should use novel approaches to trial design
to appropriately study gene and cell therapies with
potentially invasive delivery or lifelong biological effects;
efficacy should be part of the consideration for future
phase 2/3 novel trial designs, at the time a phase 1 trial is
designed and implemented.
c *Investigators should publish all clinical trial results,
negative or positive, so they are widely available to the
ALS community.
Beyond the traditional clinical trial
Background
Despite positive effects in animal models or phase 2 trials,
numerous promising therapeutics have failed during phase 3
studies over the last 20 years. Thus, a reappraisal of phase 3
methodologies is warranted because (1) many trials lack ev-
idence that the therapy either reaches the CNS or engages the
intended target, (2) drug-drug interactions between riluzole
and the investigational drug may have affected the potential
efficacy of the investigated drug, (3) more efficient and ef-
fective outcome measures are needed, including those that
combine function and survival, and (4) phenotypic and ge-
notypic heterogeneity of the ALS population has not been
considered in inclusion criteria in previous trials. However,
a lack of positive trials does not necessarily indicate a flawed
process but may reflect lack of substantial efficacy, limited
biomarkers, and limited sensitivity of the outcome measures.2
Improved regulatory trials, that aim to evaluate the efficacy of
a new intervention in a well-controlled setting with the aim of
obtaining regulatory approval, are required.2,3,44 The regula-
tory path is designed to protect patients and identify therapies
that meet the required level of proof of efficacy.
The NIH definition of a pragmatic trial is one in which ap-
proved drugs are tested in real-world settings.45 Pragmatic
trials may become a future consideration as new therapies are
proven to affect the course of the disease.
Guidelines
c Investigators may include measures of target engagement
and evidence of CNS penetration (if warranted) in the
earliest PALS treated by the therapeuticmolecule (phase 1).
c Investigators may seek to detect possible interactions of
the investigational agent with riluzole.46
c Investigators should develop more efficient and effective
outcome measures.
c Investigators should continue to aggressively pursue
disease-modifying therapies, utilizing the scientific
method that is inherent in regulatory compliant trials to
increase the likelihood that therapies become available to
PALS.
c Investigators should utilize pragmatic trial designs to
compare established interventions and determine the
external validity of positive phase 3 trials.
Discussion
A recent review of all clinical trials in ALS identified a critical
need to update the original Airlie House consensus guide-
lines.2 These guidelines were published in 1999, early on in
the ALS clinical trial experience, based on a conventional
literature review with an informal “consensus” among ALS
experts.1 The present project was undertaken to (1) update
the earlier guidelines on the basis of intervening experience,
(2) improve the efficiency and consistency of ALS clinical
trials, and (3) use modern methods of examining evidence
and establishing consensus. The modified Delphi process was
applied,12 involving 140 international stakeholders with di-
verse interests and experience, in a multistage process. This
approach was chosen to minimize bias since the option of
a truly evidence-based approach was limited by the quality of
available scientific evidence. The modified Delphi process is
a formal consensus process that decreases the risk of bias
being introduced into the guideline development process by
reducing the influence of dominant personalities and group-
think, encouraging input from all participants, and increasing
the probability that participants will change their opinions
after considering other perspectives.12 Participants share their
perspectives in a systematic way with the ultimate goal of
achieving an unbiased consensus on a set of specific guidelines
that are evidence-informed.
The 1999 guidelines briefly covered a number of statistical
issues pertaining to phase 3 clinical trials. The 2018 guidelines
include a more comprehensive statistical section that covers
guidance for all phases of clinical research. Guidance on
handling of dropouts, stratification, covariate adjustment,
time-to-failure analyses, and lead-in designs has been updated
and expanded, including discussion of predicted outcomes in
design and analysis of trials. New guidance is provided in the
following areas: pilot trial design; group-sequential methods
application; pros and cons of adaptive trial designs; use of
historical controls; biomarker development; combined anal-
ysis of survival and progression; use of linear mixed models for
repeated measurements of longitudinal outcomes; specifica-
tion and analysis of secondary outcomes; subgroup analyses;
trial registration; data standardization; and data sharing.
ALS research has advanced considerably since publication of
the previous guidelines. The introduction of 3 new areas of
e1616 Neurology | Volume 92, Number 14 | April 2, 2019 Neurology.org/N
guidelines, namely, preclinical studies (section 1), biological
and phenotypic heterogeneity (section 2), and biomarkers
(section 6) reflects this.
In line with the present initiative, adherence to best practice
guidelines and standards for preclinical treatment studies in
ALS models and biomarker studies should enhance data ac-
curacy and reproducibility, and therapeutic candidate selec-
tion before entering clinical trials.
Preclinical treatment studies have focused for years on the
first and best studied ALS model, the mutated hSOD1
(present in only 1%–2% of PALS) transgenic mouse, but this
has not led to effective therapies. Indeed, SOD1 transgenic
models do not represent sporadic or other forms of genetic
disease in patients.16,47,48 Newer models based on discoveries
of many other genes focus almost entirely on genetic forms of
ALS.47 Disease models that recapitulate key pathologies or
biological processes seen in (subsets of) sporadic PALS must
be prioritized for more successful translation of treatment
efficacy from ALS disease models to patients.49,50 The rec-
ognition that ALS is etiologically and biologically heteroge-
neous implies that multiple disease models need to be
generated to cover all ALS subsets. Yet, at the same time,
clinical research involving patients has increasingly been
recognized as essential to our understanding of disease het-
erogeneity and to the success of a precision medicine
approach.
Gene therapy strategies in patients with a SOD1 or C9orf72
mutation represent the first successful examples of such
a personalized approach. But for nonfamilial ALS, larger
datasets are required. Such datasets are best collected and
analyzed through international collaboration. Given the
degree of disease heterogeneity, data from genetics, lifestyle
and environmental studies, and patient-derived 2- and
3-dimensional (organoid) induced pluripotent stem cell
models will be required. Such datasets are best combined
with detailed phenotyping (including cognition) using in-
ternationally harmonized patient registries, neuroimaging
and neurophysiologic studies, and biomarkers from bi-
ological fluids. This approach will provide essential tools to
identify subsets of patients with shared etiology or biology
and will facilitate targeted clinical trials by enabling the se-
lection of patients most likely to benefit from a particular
experimental therapeutic approach. Allowing patients and
caregivers to participate in the design and execution of
clinical trials is another important aspect of the 2018
guidelines.
Given the rate at which the field has advanced in recent years,
we suggest a follow-up meeting to refine the guidelines within
4 years. Moreover, we view the 2018 clinical trial guidelines
not as inflexible, final, or complete, but rather as an updated
starting point for improving clinical trial design and acceler-
ating the development of effective treatments for patients
with ALS.
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